Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M
Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M
A Pennsylvania judge on Tuesday drastically reduced a $2.25 billion verdict against Bayer AG (OTC:BAYRY), cutting it down to $400 million in a case involving a man who claimed he developed cancer from using the company's Roundup weedkiller.
賓夕法尼亞的一位法官在週二大幅減少了拜耳（場外交易：拜耳(adr)）22.5億美元的裁決結果，將其削減至4億美元，該案牽涉到一名聲稱因使用該公司的Roundup殺草劑患癌症的男子。
The jury in the Philadelphia Court of Common Pleas had initially awarded John McKivison $250 million in compensatory damages and $2 billion in punitive damages, finding that his non-Hodgkin's lymphoma was caused by long-term use of Roundup at his home.
費城普通陪審法院陪審團最初授予約翰·麥克伊維森2.5億美元的補償賠償金和20億美元的懲罰性賠償金，認定他非霍奇金淋巴瘤是由於在家長期使用Roundup所致。
However, Judge Susan Schulman later adjusted the damages to $50 million in compensatory and $350 million in punitive, citing Bayer's challenges.
然而，法官蘇珊·舒爾曼後來將賠償金調整爲5000萬美元的補償和3.5億美元的懲罰性賠償金，理由是拜耳面臨的挑戰。
Bayer intends to appeal to the Superior Court of Pennsylvania, arguing that the trial included misleading and "inflammatory" testimony. Reuters noted that the company also called for legislative reform to shield companies that comply with federal labeling standards.
拜耳打算上訴至賓夕法尼亞高級法院，稱審判包括具有誤導性和“煽動性”的證言。路透社指出，該公司還呼籲立法改革，以保護遵守聯邦標籤標準的公司。
McKivison's legal team expressed satisfaction that the jury's decision to link Roundup to cancer was upheld.
麥克伊維森的法律團隊對陪審團將Roundup與癌症聯繫在一起的決定感到滿意。
However, they plan to appeal for the reinstatement of the original $2.25 billion verdict, stating that the reduction deviates from established Pennsylvania law.
然而，他們計劃上訴，尋求恢復原先的22.5億美元的裁決結果，並表示這一減少偏離了賓夕法尼亞州既定的法律。
Despite numerous studies indicating that glyphosate, the active ingredient in Roundup, is safe for human use, the product has faced extensive legal challenges.
儘管有多項研究表明Roundup的活性成分草甘膦對人類使用是安全的，但該產品面臨着廣泛的法律挑戰。
Roundup, once widely used in U.S. households, saw its home-use sales phased out by Bayer last year.
曾經被廣泛用於美國家庭的Roundup，在去年被拜耳逐步停止使用。
Bayer has faced over 165,000 claims in the U.S. alleging that Roundup causes non-Hodgkin's lymphoma. Although Bayer has won 14 of the last 20 trials, recent losses have led to over $4 billion in verdicts, shaking investor confidence and company hopes for an end to the litigation.
拜耳在美國面臨超過16.5萬個聲稱Roundup導致非霍奇金淋巴瘤的訴訟。儘管拜耳在過去的20次審判中贏得了14次，但最近的敗訴導致了超過40億美元的賠償金，動搖了投資者的信心，也削弱了公司結束訴訟的希望。
In 2020, Bayer settled many pending cases for up to $9.6 billion, but future claims remain unresolved, with more than 50,000 still pending.
2020年，拜耳爲許多待處理的案件達成了高達96億美元的和解，但未來的索賠仍未解決，仍有超過5萬個案件等待裁決。
Price Action: BAYRY shares closed at $7.79 on Tuesday.
股價行情：BAYRY股票週二收於7.79美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
Photo via Wikimedia Commons
照片通過Wikimedia Commons